Wall Street analysts forecast that DexCom (DXCM) will report quarterly earnings of $0.27 per share in its upcoming release, pointing to a year-over-year increase of 58.8%. It is anticipated that revenues will amount to $911.2 million, exhibiting an increase of 22.9% compared to the year-ago quarter.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projec ...

The Medical Instruments industry is once again in a transformative phase. With the pandemic-led crisis over now, the industry is now seeing rapid adoption of generative Artificial Intelligence (genAI) and digital therapeutics, which, according to market watchers, is expected to take the healthcare industry by storm.In fact, since the beginning of 2023, the industry has been witnessing the adoption of AI and the Internet of Medical Things in the form of digital healthcare options in hospitals and other healt ...

DexCom Inc. (DXCM) and MD Revolution recently announced their partnership, where Dexcom is likely to integrate its industry-leading continuous glucose monitoring (CGM) systems with MD Revolution’s remote care management.Dexcom’s wearable devices pair with users' smartphones to monitor glucose levels. As a result of the partnership, patients' glucose monitoring data can now be made available to clinicians through MD Revolution’s care management platform, which is likely to empower clinicians to make informed ...

MarkHatfield/E+ via Getty Images Investment Thesis DexCom (NASDAQ:DXCM) is not exactly every investor’s cup of tea. The company operates in the medical technology space, which is far away from the hype in mainstream AI, and yet, the company’s stock often confounds investors with its high valuation metrics, per my observation. Rightly so, because 93x trailing twelve-month earnings or 80x forward earnings is often considered expensive. However, I believe investors fail to observe the robust growth DexCom ...

DexCom (DXCM) closed the latest trading day at $139.94, indicating a +0.73% change from the previous session's end. The stock's performance was ahead of the S&P 500's daily loss of 0.04%. Meanwhile, the Dow lost 0.03%, and the Nasdaq, a tech-heavy index, added 0.03%.Coming into today, shares of the medical device company had gained 2.72% in the past month. In that same time, the Medical sector lost 0.6%, while the S&P 500 gained 2.57%.The investment community will be paying close attention to the earnings p ...

DexCom (DXCM) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this medical device company have returned +3.6% over the past month versus the Zacks S&P 500 composite's +1.6% change. The Zacks Medical - Instruments industry, to which DexCom belongs, has lost 0.3% over this period. Now the key question is: Where could the stock be headed in the near term?Although media re ...

DexCom (DXCM) ended the recent trading session at $136.65, demonstrating a -0.94% swing from the preceding day's closing price. This change lagged the S&P 500's daily loss of 0.72%. At the same time, the Dow lost 1%, and the tech-heavy Nasdaq lost 0.95%.Shares of the medical device company witnessed a gain of 12.79% over the previous month, beating the performance of the Medical sector with its loss of 0.03% and the S&P 500's gain of 2.16%.The investment community will be closely monitoring the performance ...

Key PointsDexCom is a leading maker of continuous glucose monitoring (CGM) systems initially serving Type 1 diabetics, which are around 5% of the diabetes population, with Type 2 being 95%.Diabetes is a growing epidemic expected to reach 780 million people worldwide by 2045.DexCom is expected to launch Stelo, its CGM system for Type 2 diabetics that doesn't require finger sticks, competing directly with Abbott Lab's Freestyle Libre.5 stocks we like better than DexComDexCom Inc. NASDAQ: DXCM is a leading med ...

DexCom (DXCM) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this medical device company have returned +13.9%, compared to the Zacks S&P 500 composite's +3.6% change. During this period, the Zacks Medical - Instruments industry, which DexCom falls in, has gained 3.9%. The key question now is: What could be the stock's future direction?While media ...

DexCom (DXCM) closed the most recent trading day at $134.17, moving -0.41% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.57%. On the other hand, the Dow registered a gain of 0.83%, and the technology-centric Nasdaq increased by 0.39%.Heading into today, shares of the medical device company had gained 15.1% over the past month, outpacing the Medical sector's gain of 0.13% and the S&P 500's gain of 2.97% in that time.The investment community will be closely ...